Medizone International has signed an agreement with ADA Innovations of Toronto, Canda to develop and manufacture its AsepticSure sterilisation technology.
Edwin Marshall, chief executive of San Francisco, California-based Medizone said Medizone had shortlisted five potential manufacturing partners, but chose ADA because it was the only company with knowledge of ozone-based technologies and experience in medical device design, building and product launch.
ADA’s founders and directors, Mark Costa and Hao (Hawk) Chen have engineering and medical device experience from previously working at Datascope Patient Monitoring (now Mindray North America), Husky, and global medical device manufacturer, Mindray International.
The final-phase development of the AsepticSure sterilisation technology is already underway, said Medizone. The four final steps involve the completion of the final commercial design and verification; regional regulatory compliance; soft product launch involving small-scale manufacturing output; and multi-sector market penetration supported by up-scaled output and the ability to outsource manufacturing capacity.
“While the transition from beta to production equipment has taken significantly longer than anticipated a year ago, the wait has been well worth it,'” said Marshall.
“We're now more confident than ever that our AsepticSure product line will far surpass any other form of sterilisation technology on the market.”
Medizone’s AsepticSure system is being developed to decontaminate and sterilise hospital surgical suites, emergency rooms, intensive care units, patient rooms, schools, cleanrooms and other critical infrastructure.
The company claims its oxidative sterilisation process delivers up to 7.1 log reductions kill rates for pathogens such as MRSA, C.Dif, Listeria and E.coli.
A government variant is being developed for bio-terrorism countermeasures with additional variants for sports facilities and food processing applications.